Rinker, Franziska Bremer, Corinna M Schröder, Kathrin Wiegand, Steffen B Bremer, Birgit Manns, Michael P Kraft, Anke R Wedemeyer, Heiner Yang, Lei Pavlovic, Vedran
...
Published in
Liver international : official journal of the International Association for the Study of the Liver
Hepatitis B virus (HBV) contains three viral surface proteins, large, middle and small hepatitis B surface protein (LHBs, MHBs, SHBs). Proportions of LHBs and MHBs are lower in patients with inactive versus active chronic infection. Interferon alfa may convert HBeAg-positive chronic hepatitis B (CHB) to an inactive carrier state, but prediction of ...
Wei, Lai Pavlovic, Vedran Bansal, Aruna T Chen, Xiaoping Foster, Graham R He, Hua Kao, Jia-Horng Lampertico, Pietro Liaw, Yun-Fan Motoc, Adriana
...
Published in
Journal of viral hepatitis
In a multicentre, genome-wide association study to identify host genetic factors associated with treatment response in adult chronic hepatitis B patients, genotype data were obtained by microarray analysis from 1669 patients who received peginterferon alfa-2a for ≥ 24 weeks with/without a nucleos(t)ide analog. Treatment response was assessed at lea...
Huang, Yan Li, Ming-Hui Hou, Min Xie, Yao
Published in
Hepatobiliary & pancreatic diseases international : HBPD INT
In this interferon-free era, PegIFN-based regimens remain a safe and effective option for selected HCV patients.
Kao, Jia-Horng Tung, Shui-Yi Lee, Younjae Thongsawat, Satawat Tanwandee, Tawesak Sheen, I-Shyan Wu, Jinzi J Li, Hui Brennan, Barbara J Zhou, Julian
...
Published in
Journal of gastroenterology and hepatology
Chronic hepatitis C is an important public health problem in Asia. We evaluated the safety, efficacy, and pharmacokinetics of fixed-dose ritonavir-boosted danoprevir plus peginterferon alfa-2a/ribavirin in treatment-naive Asian patients with chronic hepatitis C virus (HCV) genotype (G)1 infection. Treatment-naive G1 patients in Taiwan, Thailand, an...
Karne, Sheetal Mainor, Candace B Baer, Maria R
Published in
Pharmacotherapy
Peginterferon alfa-2a (PEG-IFN alfa-2a) is commonly used to treat hepatitis C virus infection and is also being used increasingly to treat myeloproliferative neoplasms including polycythemia vera. Sarcoidosis associated with IFN therapy for treatment of hepatitis C is well described, with hypercalcemia occurring as a rare manifestation. We describe...
Sandoughdaran, Saleh Alavian, Seyed Moayed Sharafi, Heidar Behnava, Bita Salimi, Shima Mehrnoush, Leila Karimi Elizee, Pegah Keshvari, Maryam
Published in
Hepatitis monthly
The present study suggests that thalassemic patients with chronic hepatitis C genotype 1 infection who did not achieve SVR after a course of therapy with Peg-IFN and RBV may benefit from being retreated with a 72-week regimen.
Bruno, Raffaele Cariti, Giuseppe Nasta, Paola Capetti, Amedeo Ravasio, Veronica Galli, Massimo Raise, Enzo Palmieri, Giulio Iannacone, Claudio Puoti, Massimo
...
Published in
Liver international : official journal of the International Association for the Study of the Liver
Undetectable HIV RNA, longer anti-HCV treatment adherence and younger age were independent SVR predictors in treatment-naïve HIV/HCV G2/3 patients receiving PEG-IFN/RBV. Suppressing HIV RNA replication before anti-HCV therapy and increasing adherence to PEG-IFN/RBV treatment SVR rates may improve SVR.
Rokx, Casper van der Ende, Marchina E Verbon, Annelies Rijnders, Bart J A
Published in
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
In this observational cohort study, 10 patients with extensive or treatment-refractory AIDS-associated Kaposi sarcoma were treated with peginterferon alfa-2a. Tumor responses were observed in 9 patients with a median progression-free survival of 645 days. Peginterferon alfa-2a could be an effective therapy for extensive or treatment-resistant Kapos...
Cao, Zhen Huan Ma, Li Na Zhang, Hong Wei Liu, Ya Li Chen, Xin Yue
Published in
Journal of digestive diseases
Extended treatment with PEG IFNα-2a with lamivudine or adefovir for 96 weeks is a promising strategy to achieve high rates of sustainable HBeAg and HBsAg seroconversion and HBV DNA suppression in patients with HBeAg-positive CHB.
Varunok, Peter Lawitz, Eric Beavers, Kimberly L Matusow, Gary Leong, Ruby Lambert, Nathalie Bernaards, Coen Solsky, Jonathan Brennan, Barbara J Wat, Cynthia
...
Published in
Patient preference and adherence
These results indicate that peginterferon alfa-2a can be successfully and safely delivered via the autoinjector and that the device is easy to handle.
